Summary

This report contains market size and forecasts of Specialty Generics in China, including the following market information:
China Specialty Generics Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Specialty Generics companies in 2020 (%)
The global Specialty Generics market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China Specialty Generics market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Specialty Generics Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Specialty Generics Market, By Type, 2016-2021, 2022-2027 ($ Millions)
China Specialty Generics Market Segment Percentages, By Type, 2020 (%)
Injectables
Oral
Others

China Specialty Generics Market, By Application, 2016-2021, 2022-2027 ($ Millions)
China Specialty Generics Market Segment Percentages, By Application, 2020 (%)
Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Specialty Generics revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Specialty Generics revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva Pharmaceuticals Industries
Akorn, Inc.
Mylan N.V.
Mallinckrodt
Sandoz International GmbH
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals
Apotex Corp.
Endo International plc.

ページTOPに戻る

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Specialty Generics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Specialty Generics Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year

2 China Specialty Generics Overall Market Size
2.1 China Specialty Generics Market Size: 2021 VS 2027
2.2 China Specialty Generics Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints

3 Company Landscape
3.1 Top Specialty Generics Players in China Market
3.2 Top China Specialty Generics Companies Ranked by Revenue
3.3 China Specialty Generics Revenue by Companies
3.4 Top 3 and Top 5 Specialty Generics Companies in China Market, by Revenue in 2020
3.5 Companies Specialty Generics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Specialty Generics Players in China Market
3.6.1 List of Tier 1 Specialty Generics Companies in China
3.6.2 List of Tier 2 and Tier 3 Specialty Generics Companies in China

4 Sights by Type
4.1 Overview
4.1.1 By Type - China Specialty Generics Market Size Markets, 2021 & 2027
4.1.2 Injectables
4.1.3 Oral
4.1.4 Others
4.2 By Type - China Specialty Generics Revenue & Forecasts
4.2.1 By Type - China Specialty Generics Revenue, 2016-2021
4.2.2 By Type - China Specialty Generics Revenue, 2022-2027
4.2.3 By Type - China Specialty Generics Revenue Market Share, 2016-2027

5 Sights by Application
5.1 Overview
5.1.1 By Application - China Specialty Generics Market Size, 2021 & 2027
5.1.2 Retail Pharmacies
5.1.3 Specialty Pharmacies
5.1.4 Hospital Pharmacies
5.2 By Application - China Specialty Generics Revenue & Forecasts
5.2.1 By Application - China Specialty Generics Revenue, 2016-2021
5.2.2 By Application - China Specialty Generics Revenue, 2022-2027
5.2.3 By Application - China Specialty Generics Revenue Market Share, 2016-2027

6 Specialty Generics Companies Profiles
6.1 Teva Pharmaceuticals Industries
6.1.1 Teva Pharmaceuticals Industries Company Details
6.1.2 Teva Pharmaceuticals Industries Business Overview
6.1.3 Teva Pharmaceuticals Industries Specialty Generics Introduction
6.1.4 Teva Pharmaceuticals Industries Specialty Generics Revenue in China Market (2016-2021)
6.1.5 Teva Pharmaceuticals Industries Recent Developments
6.2 Akorn, Inc.
6.2.1 Akorn, Inc. Company Details
6.2.2 Akorn, Inc. Business Overview
6.2.3 Akorn, Inc. Specialty Generics Introduction
6.2.4 Akorn, Inc. Specialty Generics Revenue in China Market (2016-2021)
6.2.5 Akorn, Inc. Recent Developments
6.3 Mylan N.V.
6.3.1 Mylan N.V. Company Details
6.3.2 Mylan N.V. Business Overview
6.3.3 Mylan N.V. Specialty Generics Introduction
6.3.4 Mylan N.V. Specialty Generics Revenue in China Market (2016-2021)
6.3.5 Mylan N.V. Recent Developments
6.4 Mallinckrodt
6.4.1 Mallinckrodt Company Details
6.4.2 Mallinckrodt Business Overview
6.4.3 Mallinckrodt Specialty Generics Introduction
6.4.4 Mallinckrodt Specialty Generics Revenue in China Market (2016-2021)
6.4.5 Mallinckrodt Recent Developments
6.5 Sandoz International GmbH
6.5.1 Sandoz International GmbH Company Details
6.5.2 Sandoz International GmbH Business Overview
6.5.3 Sandoz International GmbH Specialty Generics Introduction
6.5.4 Sandoz International GmbH Specialty Generics Revenue in China Market (2016-2021)
6.5.5 Sandoz International GmbH Recent Developments
6.6 Pfizer, Inc.
6.6.1 Pfizer, Inc. Company Details
6.6.2 Pfizer, Inc. Business Overview
6.6.3 Pfizer, Inc. Specialty Generics Introduction
6.6.4 Pfizer, Inc. Specialty Generics Revenue in China Market (2016-2021)
6.6.5 Pfizer, Inc. Recent Developments
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Sun Pharmaceutical Industries Ltd. Company Details
6.7.2 Sun Pharmaceutical Industries Ltd. Business Overview
6.7.3 Sun Pharmaceutical Industries Ltd. Specialty Generics Introduction
6.7.4 Sun Pharmaceutical Industries Ltd. Specialty Generics Revenue in China Market (2016-2021)
6.7.5 Sun Pharmaceutical Industries Ltd. Recent Developments
6.8 Valeant Pharmaceuticals
6.8.1 Valeant Pharmaceuticals Company Details
6.8.2 Valeant Pharmaceuticals Business Overview
6.8.3 Valeant Pharmaceuticals Specialty Generics Introduction
6.8.4 Valeant Pharmaceuticals Specialty Generics Revenue in China Market (2016-2021)
6.8.5 Valeant Pharmaceuticals Recent Developments
6.9 Apotex Corp.
6.9.1 Apotex Corp. Company Details
6.9.2 Apotex Corp. Business Overview
6.9.3 Apotex Corp. Specialty Generics Introduction
6.9.4 Apotex Corp. Specialty Generics Revenue in China Market (2016-2021)
6.9.5 Apotex Corp. Recent Developments
6.10 Endo International plc.
6.10.1 Endo International plc. Company Details
6.10.2 Endo International plc. Business Overview
6.10.3 Endo International plc. Specialty Generics Introduction
6.10.4 Endo International plc. Specialty Generics Revenue in China Market (2016-2021)
6.10.5 Endo International plc. Recent Developments

7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer